CN116298277A - Sample treatment fluid and application thereof - Google Patents

Sample treatment fluid and application thereof Download PDF

Info

Publication number
CN116298277A
CN116298277A CN202310358223.4A CN202310358223A CN116298277A CN 116298277 A CN116298277 A CN 116298277A CN 202310358223 A CN202310358223 A CN 202310358223A CN 116298277 A CN116298277 A CN 116298277A
Authority
CN
China
Prior art keywords
sample
base liquid
sample processing
final concentration
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310358223.4A
Other languages
Chinese (zh)
Inventor
易嘉乐
刘春艳
罗沛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fapon Biotech Inc
Guangdong Fapon Biotech Co Ltd
Original Assignee
Fapon Biotech Inc
Guangdong Fapon Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fapon Biotech Inc, Guangdong Fapon Biotech Co Ltd filed Critical Fapon Biotech Inc
Priority to CN202310358223.4A priority Critical patent/CN116298277A/en
Publication of CN116298277A publication Critical patent/CN116298277A/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention discloses a sample treatment fluid and application thereof. According to the invention, the amphoteric surfactant and the nonionic surfactant for salt parallel connection are added into the sample treatment liquid, so that the sensitivity of immunodetection can be effectively improved.

Description

Sample treatment fluid and application thereof
Technical Field
The present invention relates to the field of biotechnology. In particular, the invention discloses a sample treatment fluid and application thereof.
Background
RNA enveloped viruses are a large family of RNA viruses, and the RNA virus particles are provided with lipid envelopes, so that the viruses can enter and exit target cells through the envelopes, and the RNA enveloped viruses have strong infection capacity. Common influenza viruses and coronaviruses all belong to RNA-enveloped viruses. 2019 novel coronavirus (2019-nCoV) is the 7 th currently known coronavirus that can infect humans.
The immunological detection is based on the immunological principle of antigen-antibody specific binding, and common methods mainly include immunochromatography detection, ELISA detection or chemiluminescence detection. Different samples are complicated in composition and large in variation, and if no corresponding treatment is performed, nonspecific reactions other than antigen-antibody binding easily occur, resulting in generation of adverse cross reactions, reduction in detection sensitivity, and the like.
Taking new coronavirus detection as an example, the currently marketed immunological detection products have low sensitivity and risk of missed detection. The present invention has been proposed to further improve the detection sensitivity.
Disclosure of Invention
In order to improve the sensitivity of the existing immunodetection products, the invention discloses a method for improving the detection sensitivity by contacting a sample to be detected with a sample treatment liquid containing a soluble magnesium salt in immunodetection of antigen-antibody reaction with a component to be detected.
The invention includes the following embodiments:
a sample processing method in immunodetection is to make a sample to be detected contact with a sample processing liquid containing soluble magnesium salt.
In some embodiments, the sample may be any sample suspected of containing the component to be tested, such as, without limitation, a pharyngeal swab collection sample, an oropharyngeal swab collection sample, a nasopharyngeal swab collection sample, a sputum sample, an alveolar lavage sample, a peripheral blood sample, a plasma sample, or a serum sample; in some embodiments, the sample is, but not limited to, a pharyngeal swab or a nasopharyngeal swab, for example.
In some embodiments, the sample is a sample containing a component to be tested; in some embodiments, the component to be detected is an RNA virus; in some embodiments, the RNA virus is an RNA enveloped virus; in some embodiments, the RNA-enveloped virus is at least any one of a coronavirus or an influenza virus; in some embodiments, the RNA enveloped virus is, for example, 2019-nCoV, such as SARS, or such as influenza virus, but is not limited thereto.
In the present invention, contacting the sample to be detected with the sample processing liquid includes, for example, adding the sample to be detected to the sample processing liquid, mixing the sample to be detected with the sample processing liquid, adding the sample to be detected to an immunoassay tool (for example, a sample pad in immunochromatography), adding the sample to be detected and the sample processing liquid to the immunoassay tool (for example, a sample pad in immunochromatography), respectively, fixing the sample processing liquid to the immunoassay tool (for example, a sample pad in immunochromatography), adding the sample to be detected, or a combination of the above forms.
In some embodiments, the final concentration of soluble magnesium salt in the sample treatment fluid is 10 to 400mM; in some embodiments, the final concentration of soluble magnesium salt in the sample treatment fluid is 40-160mM; in some embodiments, the final concentration of soluble magnesium salt in the sample treatment fluid is 80-160mM; in some embodiments, the final concentration of the soluble magnesium salt in the sample treatment fluid includes, but is not limited to, e.g., 10mM, e.g., 40mM, e.g., 80mM, e.g., 160mM, e.g., 200mM, e.g., 260mM, e.g., 320mM, e.g., 380mM, e.g., 400 mM.
In some embodiments, the final concentration of the amphoteric surfactant S9 in the sample treatment fluid is 0.1-1.5 (w/v); in some embodiments, the final concentration of S9 in the sample processing fluid is 0.25-1 (w/v)%; in some embodiments, the final concentration of S9 in the sample processing fluid is 0.5-1 (w/v)%; in some embodiments, the final concentration of S9 in the sample processing liquid includes, for example, 0.1 (w/v)%, such as 0.25 (w/v)%, such as 0.5 (w/v)%, such as 1 (w/v)%, such as 1.2 (w/v)%, such as 1.5 (w/v)%, but is not limited thereto.
In some embodiments, the sample processing fluid further comprises a buffer; in some embodiments, the buffer includes, for example, tris-HCl, such as PB (phosphate buffer), such as BB (borate buffer), but is not limited thereto. In some embodiments, the buffer component is used at a concentration of 10-50mM; in some embodiments, the buffer component is used at a concentration including, but not limited to, e.g., 10mM, e.g., 15mM, e.g., 25mM, e.g., 30mM, e.g., 35mM, e.g., 40mM, e.g., 50 mM. In some embodiments, the pH of the buffer is 8.0-9.5; in some embodiments, the pH of the buffer includes, but is not limited to, e.g., 8.0, e.g., 8.2, e.g., 8.5, e.g., 8.8, e.g., 9.0, e.g., 9.2, e.g., 9.5.
In some embodiments, the sample processing fluid further comprises an inert protein; in some embodiments, the inert protein includes, for example, casein, such as BSA, but is not limited thereto. In some embodiments, the final concentration of inert protein in the sample processing fluid is 0.3-1 (w/v)%; in some embodiments, the final concentration of the inert protein in the sample processing fluid includes, for example, 0.3 (w/v)%, such as 0.5 (w/v)%, such as 0.8 (w/v)%, such as 1 (w/v)%, but is not limited thereto.
In some embodiments, the sample processing fluid further comprises sodium chloride; in some embodiments, the final concentration of sodium chloride in the sample treatment fluid is 50-200mM; in some embodiments, the final concentration of sodium chloride in the sample processing fluid includes, for example, 50mM, such as 100mM, such as 150mM, such as 200mM, but is not limited thereto.
In some embodiments, the sample processing fluid further comprises a nonionic surfactant; the nonionic surfactant can improve the hydrophilicity and the wettability, reduce the surface tension of the liquid, and is beneficial to improving the detection signal of the component to be detected, and the specific effect is required to depend on the compatibility between the surfactant and other matrixes; in some embodiments, the nonionic surfactant includes, but is not limited to, for example, tween 20 (tween 20), for example tween 40 (tween 40), for example Pluronic F-127 (plarnike F127), for example Triton X-405 (Triton 405), for example Triton X-100 (Triton 100).
In some embodiments, the final concentration of nonionic surfactant in the sample treatment fluid is 0.1-1.5 (w/v); in some embodiments, the final concentration of the nonionic surfactant in the sample treatment fluid is 0.25-1 (w/v)%; in some embodiments, the final concentration of the nonionic surfactant in the sample treatment fluid is 0.5-1 (w/v)%; in some embodiments, the final concentration of the nonionic surfactant in the sample processing liquid includes, for example, 0.1 (w/v)%, such as 0.25 (w/v)%, such as 0.5 (w/v)%, such as 1 (w/v)%, such as 1.2 (w/v)%, such as 1.5 (w/v)%, but is not limited thereto.
In some embodiments, the sample processing fluids of the present invention are used in immunoassays. The term "immunoassay" as used herein is to be understood in a broad sense and refers to a detection method by specific binding of an antigen-antibody, including, but not limited to, immunochromatographic detection, e.g., ELISA detection, e.g., chemiluminescent detection. It will be appreciated by those skilled in the art that the sample processing fluid of the present invention may be used in an immunoassay for an antigen or antibody. In some embodiments, for example, a sample containing the novel coronavirus is contacted with the sample treatment solution of the invention, and then subjected to antigen-antibody reaction with the labeled, coated end protein, thereby realizing the effect of detecting the novel coronavirus.
In some embodiments, the present disclosure encompasses the sample processing fluids of any of the preceding embodiments.
In some embodiments, the test kits or test strips of the invention comprise a sample processing fluid of any of the preceding embodiments. The detection kit of the invention is to be understood in a broad sense and mainly refers to a tool for carrying reagents related to the immunological detection. In some embodiments, the detection kit may further comprise a number of kit-of-parts. The detection test strip comprises absorbent paper, a marker binding pad, a coating film, a sample pad and a bottom plate.
Detailed Description
The present invention will be described in further detail with reference to the following examples. The following examples are provided to illustrate embodiments of the invention and are not intended to limit the invention. The invention may optionally include embodiments not shown by way of example.
Methods not described in detail in the detailed description may refer to conventional methods or manufacturer's instructions in the art; reagents not described in the detailed description are available commercially.
In the present invention, the definition of soluble magnesium salt means that for 1g (ml) of magnesium salt, the volume of solvent required for dissolution is <100ml, i.e. soluble magnesium salt.
In the present invention, the concentration unit mM means mmol/L, and M means mol/L.
Marking
And (3) diluting protein capable of reacting with antigen and antibody of the component to be detected, marking on colloidal gold particles with the particle size of 30-80nm, adding BSA after marking, centrifuging, removing supernatant, redissolving colloidal gold precipitate by using a protective solution, dripping the redissolved colloidal gold into a glass cellulose membrane, and drying to obtain the marker binding pad.
Coating
Protein which can react with antigen and antibody of the detected component is diluted and then coated on a nitrocellulose membrane, and the membrane dividing parameter is 1.0 mu l/cm. And (3) after coating, drying in a forced air drying oven at 37 ℃ for 2 hours to obtain the coating film.
Assembly
And assembling the marker binding pad and the coating film with other materials (a bottom plate, absorbent paper and a sample pad), cutting into 2.5mm pieces, and preparing the corresponding immunodetection test strip.
Example 1
(base liquid 1) formula of base liquid 1: 0.5 (w/v)% casein, 150mM NaCl,25mM Tris-HCl, pH 9.0;
(base liquid 1-1) formula of base liquid 1-1: 1.0 (w/v)% anhydrous sodium sulfate was added to the base liquid 1;
(base liquid 1-2) formula of base liquid 1-2: 1.0 (w/v)% trisodium citrate is added to the base liquid 1;
(base liquid 1-3) formula of base liquid 1-3: 1.0 (w/v)% lithium chloride was added to the base liquid 1;
(base liquid 1-4) formula of base liquid 1-4: 1.0 (w/v)% magnesium chloride was added to the base liquid 1;
(base liquid 1-5) formula of base liquid 1-5: 1.0 (w/v)% magnesium sulfate was added to the base liquid 1;
to explore the best salt composition in the sample treatment fluid, the performance of several salts was compared.
And (3) dripping the components serving as a sample treatment liquid to a blank sample pad, drying, assembling to an immunochromatography device, and dripping a new coronavirus quality control product subjected to gradient dilution onto the treated sample pad during detection.
The result is recorded as the read value of the colloidal gold color card, and the smaller the value is, the stronger the color development is, which indicates that the higher the sensitivity is.
As a result, as shown in Table 1, when a soluble magnesium salt was added to the base liquid 1, the sensitivity was improved.
Table 1, test results of example 1
Quality control product 1μg/ml 0.1μg/ml 25ng/ml 0.5ng/ml
Base liquid 1 C3 C5 C8 B
Base liquid 1-1 C2 C4+ C7 C9
Base liquid 1-2 C3+ C4 C7 C9
Base liquid 1-3 C3+ C4- C7+ B
Base liquid 1-4 C2+ C3- C7+ C9
Base liquid 1-5 C2+ C3 C6 C9
Example 2
(base liquid 2) formula of base liquid 2: 0.5 (w/v)% casein, 150mM NaCl,80mM magnesium sulfate, 25mM Tris-HCl, pH 9.0;
(base liquid 2-1) formula of base liquid 2-1: adding 0.5 (w/v)% tween 20 to the base liquid 2;
(base liquid 2-2) formula of base liquid 2-2: adding 0.5 (w/v)% tween 40 to the base liquid 2;
(base liquid 2-3) formula of base liquid 2-3: 0.5 (w/v)% Pluronic F-127 was added to base liquid 2;
(base liquid 2-4) formula of base liquid 2-4: adding 0.5 (w/v)% Triton X-405 to base liquid 2;
(base liquid 2-5) formula of base liquid 2-5: adding 0.5 (w/v)% Triton X-100 to base liquid 2;
(base liquid 2-6) formula of base liquid 2-6: 0.5 (w/v)% S9 was added to the base liquid 2;
to further explore the optimal surfactant component in the treatment fluid, the performance of several surfactants was compared. The method of using the base liquid as a sample treatment liquid was the same as in example 1.
As a result, as shown in Table 2, when S9 was added to the base liquid 2, the sensitivity was higher than that of the other surfactants.
Table 2, test results of example 2
Quality control product 0.1μg/ml 25ng/ml 5ng/ml 0.5ng/ml 0.1ng/ml
Base liquid 2 C3 C6 C8 C9 B
Base liquid 2-1 C3 C6+ C8+ C9+ C9-
Base liquid 2-2 C3 C6+ C8+ C9+ C9-
2-3 parts of base liquid C3+ C5 C8 C9+ C9-
2-4 parts of base liquid C3+ C5 C8 C9+ C9-
2-5 parts of base liquid C3+ C5 C8 C9+ C9-
2-6 parts of base liquid C2 C4 C7 C8 C9
Example 3
(base liquid 3) formula of base liquid 3: 0.5 (w/v)% casein, 150mM NaCl,80mM magnesium sulfate, 0.5 (w/v)% S9, 25mM Tris-HCl, pH 9.0;
(base liquid 3-1) formula of base liquid 3-1: 0.5 (w/v)% tween 20 was added to the base liquid 3;
(base liquid 3-2) formula of base liquid 3-2: adding 0.5 (w/v)% tween 40 to the base liquid 3;
(base liquid 3-3) formula of base liquid 3-3: 0.5 (w/v)% Pluronic F-127 was added to base liquid 3;
(base liquid 3-4) formula of base liquid 3-4: adding 0.5 (w/v)% Triton X-405 to the base liquid 3;
(base liquid 3-5) formula of base liquid 3-5: adding 0.5 (w/v)% Triton X-100 to the base liquid 3;
to further increase the sensitivity, the dominant surfactant S9 obtained in example 2 was used in combination with other surfactants. The method of using the base liquid as a sample treatment liquid was the same as in example 1.
As shown in Table 3, since the sensitivity was further improved when S9 and Triton X-100 were combined, the sample treatment solution obtained by introducing magnesium sulfate and combining S9 and Triton X-100 was designated as COV-SP and was subjected to the subsequent optimization.
Table 3, test results of example 3
Quality control product 0.1μg/ml 25ng/ml 5ng/ml 0.5ng/ml 0.1ng/ml
Base liquid 3 C2 C4 C7 C8 C9
Base liquid 3-1 C2 C4 C7 C8 C9
Base liquid 3-2 C2 C4 C7 C8 C9
Base liquid 3-3 C2 C4 C7 C8 C9
Base liquid 3-4 C2 C4+ C7 C8 C9
3-5 parts of base liquid C2+ C3 C6 C8 C9
Example 4
(S1) formulation of S1 sample treatment solution: consistent with COV-SP except that no magnesium sulfate was added;
(S2) formulation of S2 sample treatment solution: consistent with COV-SP except that the magnesium sulfate concentration therein was changed to 40mM;
(S3) formulation of S3 sample treatment solution: consistent with COV-SP except that the magnesium sulfate concentration therein was changed to 160mM;
COV-SP was compared with the formulations of examples S1-S3. The sample treatment liquid was used in the same manner as in example 1.
The results are shown in Table 4, and the sensitivity of the group (COV-SP) into which magnesium sulfate was introduced was about 1C higher than that of the group (S1) into which magnesium sulfate was not introduced; the magnesium sulfate dosage is reduced to 40mM or increased to 160mM, and the sensitivity is consistent with COV-SP; 100 samples of the throat swab of the healthy person are taken for specificity verification, and no false positive is detected.
Table 4, test results of example 4
Quality control product 1μg/ml 0.1μg/ml 25ng/ml 5ng/ml 0.5ng/ml 0.1ng/ml
S1 C1 C3 C4 C7 C9 B+
S2 C1+ C2+ C3 C6 C8 C9
S3 C1+ C2+ C3 C6 C8 C9
COV-SP C1+ C2+ C3 C6 C8 C9
Example 5
(S4) formulation of S4 sample treatment solution: consistent with COV-SP except that the 0.5 (w/v)% S9+0.5 (w/v)% Triton X-100 combination group was replaced with 1 (w/v)% S9;
(S5) formulation of S5 sample treatment solution: consistent with COV-SP except that the 0.5 (w/v)% S9+0.5 (w/v)% Triton X-100 combination group was replaced with 1 (w/v)% Triton X-100;
(S6) formulation of S6 sample treatment solution: consistent with COV-SP except that the S9 concentration therein was changed to 0.25 (w/v)%;
(S7) formulation of S7 sample treatment solution: consistent with COV-SP except that the S9 concentration therein was changed to 1 (w/v)%;
(S8) formulation of S8 sample treatment solution: consistent with COV-SP except that Triton X-100 concentration therein was changed to 0.25 (w/v)%;
(S9) formulation of S9 sample treatment solution: consistent with COV-SP except that Triton X-100 concentration therein was changed to 1 (w/v)%;
COV-SP was compared with the formulations of examples S4-S9. The sample treatment liquid was used in the same manner as in example 1.
As a result, as shown in Table 5, it was found that either S9 (S4) alone or Triton X-100 (S5) alone was less sensitive than the combination of both. 100 samples of the throat swab of the healthy person are taken for specificity verification, and no false positive is detected.
Table 5, test results of example 5
Quality control product 1μg/ml 0.1μg/ml 25ng/ml 5ng/ml 0.5ng/ml 0.1ng/ml
S4 C1 C3+ C4 C7 C8- B+
S5 C1 C2 C4+ C7+ C8 C9
S6 C1+ C2+ C3 C6 C8 C9
S7 C1+ C2+ C3 C6 C8 C9
S8 C1 C2 C4+ C7+ C8- C9-
S9 C1+ C2+ C3 C6 C8 C9
COV-SP C1+ C2+ C3 C6 C8 C9
Example 6
(COV-SP-B) formulation of COV-SP-B sample treatment fluid: consistent with COV-SP except that 25mM Tris-HCl, pH 9.0 was changed to 25mM PB, pH 8.0;
(COV-SP-C) formulation of COV-SP-C sample treatment fluid: consistent with COV-SP except that 25mM Tris-HCl, pH 9.0 was changed to 25mM BB, pH 9.0;
COV-SP was compared with the COV-SP-B, COV-SP-C formulation of this example. The sample treatment liquid was used in the same manner as in example 1.
The results of comparing COV-SP-B, COV-SP-C with COV-SP are shown in Table 6, and it can be obtained that the sensitivity can reach the same level as Tris-HCl by using other buffer systems such as phosphate buffer and boric acid buffer instead.
Table 6, test results of example 6
Quality control product 0.1μg/ml 25ng/ml 5ng/ml 0.5ng/ml 0.1ng/ml
COV-SP-B C2+ C3 C6 C8 C9
COV-SP-C C2+ C3 C6 C8 C9
COV-SP C2+ C3 C6 C8 C9
Example 7
Mode 1: mixing COV-SP as sample diluent with the quality control product of the novel coronavirus, and dripping the mixture to a blank sample pad;
mode 2: COV-SP was used as both the sample diluent (same as in example 1) and the sample pad treatment solution (same as in example 1);
the results are shown in Table 7, and the sensitivity can be greatly improved by adding COV-SP after being uniformly mixed with the sample into an immunoassay tool; the two treatment modes are overlapped and used, and the sensitivity is equivalent.
100 samples of the throat swab of a healthy person are taken for specificity verification, and no false positive is detected.
Table 7, test results of example 7
Quality control product 1μg/ml 0.1μg/ml 25ng/ml 5ng/ml 0.5ng/ml 0.1ng/ml
Mode 1 C1+ C2+ C3 C6 C8 C9
Mode 2 C1+ C2+ C3 C6 C8 C9
Example 8
COV-SP was used as a sample treatment solution for detecting influenza virus, and was compared with base solution 1. The sample treatment liquid was used in the same manner as in example 1.
As shown in Table 8, the application of COV-SP to influenza items also greatly improved the sensitivity of detection.
Table 8, test results of example 8
Quality control product Influenza B virus/1K Influenza B virus/5K Influenza B virus/10K
Base liquid 1 C4 C9 B
COV-SP C2+ C7 C8
Example 9
COV-SP was used as a sample treatment solution for detecting SARS virus, and compared with base solution 1. The sample treatment liquid was used in the same manner as in example 1.
As shown in Table 9, the application of COV-SP to SARS item also greatly improves the sensitivity of detection.
Table 9, test results of example 9
Quality control product 5μg/ml 1μg/ml 0.5μg/ml 50ng/ml 10ng/ml 5ng/ml
Base liquid 1 C2 C3 C4 C8 C9- B
COV-SP C1+ C1 C2- C6 C8 C9
The foregoing description of the embodiments has been provided for the purpose of illustrating the general principles of the invention, and is not meant to limit the invention thereto, but to limit the invention thereto, and any modifications, equivalents, improvements and equivalents thereof may be made without departing from the spirit and principles of the invention.

Claims (9)

1. A method for treating a sample in an immunoassay for RNA-enveloped viruses, characterized in that the sample to be examined is brought into contact with a sample treatment liquid containing a soluble magnesium salt, the sample treatment liquid further containing S9.
2. The method of claim 1, wherein the soluble magnesium salt in the sample processing fluid comprises at least any one of magnesium sulfate and magnesium chloride.
3. The method of claim 1, wherein the final concentration of soluble magnesium salt in the sample processing fluid is 10-400mM;
optionally, the final concentration of the soluble magnesium salt in the sample processing fluid is 40-160mM;
optionally, the final concentration of the soluble magnesium salt in the sample processing fluid is 80-160mM.
4. The method of claim 1, wherein the final concentration of S9 in the sample processing fluid is 0.1-1.5 (w/v)%;
optionally, the final concentration of S9 in the sample processing liquid is 0.25-1 (w/v)%;
optionally, the final concentration of S9 in the sample processing liquid is 0.5-1 (w/v)%.
5. The method of any one of claims 1-4, wherein the sample processing fluid further comprises at least any one of a buffer, an inert protein, sodium chloride, a nonionic surfactant; for example, the nonionic surfactant is tween 20, tween 40, pluronic F-127, triton X-405 or Triton X-100; for example, the final concentration of the nonionic surfactant in the sample processing liquid is 0.1 to 1.5 (w/v)%; further 0.25-1 (w/v)%; further 0.5-1 (w/v)%.
6. The method of claim 1, wherein the sample is a sample containing a component to be tested;
alternatively, the RNA-enveloped virus is at least any one of coronavirus or influenza virus, such as 2019-nCoV, e.g., SARS.
7. The method of claim 1, wherein the immunoassay is an immunochromatographic assay, an ELISA assay, or a chemiluminescent assay.
8. The sample processing fluid of any one of claims 1-7.
9. A test kit or test strip comprising the sample processing fluid of claim 8.
CN202310358223.4A 2020-09-03 2020-09-03 Sample treatment fluid and application thereof Pending CN116298277A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310358223.4A CN116298277A (en) 2020-09-03 2020-09-03 Sample treatment fluid and application thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202310358223.4A CN116298277A (en) 2020-09-03 2020-09-03 Sample treatment fluid and application thereof
CN202010916312.2A CN111983217B (en) 2020-09-03 2020-09-03 Sample treatment fluid and application thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202010916312.2A Division CN111983217B (en) 2020-09-03 2020-09-03 Sample treatment fluid and application thereof

Publications (1)

Publication Number Publication Date
CN116298277A true CN116298277A (en) 2023-06-23

Family

ID=73447504

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310358223.4A Pending CN116298277A (en) 2020-09-03 2020-09-03 Sample treatment fluid and application thereof
CN202010916312.2A Active CN111983217B (en) 2020-09-03 2020-09-03 Sample treatment fluid and application thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010916312.2A Active CN111983217B (en) 2020-09-03 2020-09-03 Sample treatment fluid and application thereof

Country Status (2)

Country Link
CN (2) CN116298277A (en)
WO (1) WO2022048177A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116298277A (en) * 2020-09-03 2023-06-23 菲鹏生物股份有限公司 Sample treatment fluid and application thereof
CN114015806B (en) * 2021-10-29 2024-01-30 杭州金域医学检验所有限公司 Coronavirus quality control product diluent and preparation method and application thereof
CN113985028A (en) * 2021-11-25 2022-01-28 济南百博生物技术股份有限公司 Diluent for colloidal gold method antigen detection
CN114675017A (en) * 2022-03-25 2022-06-28 艾康生物技术(杭州)有限公司 Biological sample extracting solution and application and using method thereof
CN115047187A (en) * 2022-07-26 2022-09-13 石家庄希宝生物科技有限公司 Test strip sample pad treatment solution, preparation method and application thereof
CN115951043A (en) * 2023-03-09 2023-04-11 天津博奥赛斯生物科技股份有限公司 Sample treatment fluid for detecting neocorona antigen colloidal gold

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH095326A (en) * 1995-06-22 1997-01-10 Ss Pharmaceut Co Ltd Immunological gold colloid measuring method
US6743597B1 (en) * 2000-06-13 2004-06-01 Lifescan, Inc. Compositions containing a urea derivative dye for detecting an analyte and methods for using the same
EP3216462A3 (en) * 2010-02-26 2017-12-20 Novo Nordisk A/S Stable antibody containing compositions
JP5567932B2 (en) * 2010-08-03 2014-08-06 田中貴金属工業株式会社 Reagent composition for immunochromatography and measuring method using the same
WO2012115221A1 (en) * 2011-02-25 2012-08-30 三菱化学メディエンス株式会社 Method for measuring myocardial troponin
CN102768275A (en) * 2012-07-10 2012-11-07 北京陆桥技术有限责任公司 Staphylococcal enterotoxin assay kit, method for preparing same and application
KR102301851B1 (en) * 2013-09-10 2021-09-14 덴카 주식회사 Sample processing method for influenza virus immunoassay, and immunoassay method
CN105754956B (en) * 2016-03-16 2020-05-26 上海市浦东新区疾病预防控制中心 Sample pretreatment liquid for detecting and separating respiratory viruses of sample
KR101782859B1 (en) * 2016-03-29 2017-09-28 원광대학교산학협력단 Kit for detecting influenza virus using quantum dot-latex bead-influenza virus antibody complex and detecting method using the same
CN106771250B (en) * 2017-01-06 2018-08-21 杭州京北生物科技有限公司 A kind of luciferase co-immunoprecipitation kit for detecting mammal Lyme disease
CN108535490A (en) * 2017-03-06 2018-09-14 苏州和锐生物科技有限公司 Biological agent blood concentration detection method and reagent
CN111321247B (en) * 2018-12-17 2022-09-30 北京亿森宝生物科技有限公司 Freeze-drying microporous plate, kit and method for identifying African swine fever virus, swine fever wild strain and swine fever lapinized attenuated vaccine strain
CN110554203B (en) * 2019-09-17 2022-10-21 浙江大学山东工业技术研究院 High density lipoprotein cholesterol test paper
CN110907649A (en) * 2019-12-23 2020-03-24 山东莱博生物科技有限公司 Kit for detecting short-chain fatty acid and application thereof
CN111500769A (en) * 2020-03-11 2020-08-07 南京农业大学 Fluorescence immunochromatography method for detecting SARS-CoV-2 nucleic acid
CN111426831B (en) * 2020-03-24 2023-09-15 山东康华生物医疗科技股份有限公司 Kit for combined detection of 2019 novel coronavirus IgM and IgG antibodies and preparation method thereof
CN111337682B (en) * 2020-05-18 2020-09-08 博奥赛斯（天津）生物科技有限公司 Novel coronavirus IgM/IgG magnetic particle chemiluminescence immunoassay kit
CN111537748B (en) * 2020-06-10 2022-09-02 生物岛实验室 Test strip and kit for detecting novel human coronavirus IgM antibody and preparation method thereof
CN111537747B (en) * 2020-06-10 2022-09-02 生物岛实验室 Test strip and kit for detecting novel human coronavirus IgG antibody and preparation method thereof
CN116298277A (en) * 2020-09-03 2023-06-23 菲鹏生物股份有限公司 Sample treatment fluid and application thereof

Also Published As

Publication number Publication date
CN111983217B (en) 2023-05-02
CN111983217A (en) 2020-11-24
WO2022048177A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
CN111983217B (en) Sample treatment fluid and application thereof
EP1826562B1 (en) Method of pretreating specimen and immunoassay method using the same
CN112730839B (en) Kit for measuring content of cytokeratin 19 fragments by magnetic particle chemiluminescence method
JP6429781B2 (en) Sample processing method and immunoassay method for immunoassay of influenza virus
US20110053181A1 (en) Method for detecting objective substance and kit for detecting objective substance
CN112014575B (en) CYFRA21-1 determination kit and preparation method thereof
JP4704662B2 (en) Immunological latex turbidimetric analysis method and reagent
KR920007686B1 (en) Extraction composition test kit and their use to extract or determine herpes simplex viral antigen
CN108398564B (en) anti-TORCH-IgG type antibody spectrum chip, preparation method thereof and TORCH detection kit
JP7209498B2 (en) Immunoassay method for hepatitis B virus core antibody
JP4115728B2 (en) Composition for flow-through type inspection method, kit and inspection method using the same
EP3511712A1 (en) Method and reagent for measuring thyroglobulin
JPH03502248A (en) Aqueous washing solution for assay, diagnostic test kit and method for measuring herpes simplex virus
CN116298297A (en) Colloidal gold chromatographic test strip for simultaneously detecting syncytial virus and novel coronavirus antigen
EP4206181A1 (en) Test reagent with improved specificity by suppressing false negatives
CN113281503B (en) Reagent for splitting virus sample
CN114414799A (en) New coronavirus detection chromatography reagent strip, kit and preparation method thereof
CN109613239B (en) Group A rotavirus detection test paper
CN111208292A (en) Immunodetection kit for mycoplasma pneumoniae antibody IgM, preparation method and use method thereof
CN111239411A (en) Immunodetection kit for mycoplasma pneumoniae antibody IgG, preparation method and use method thereof
CN114859042B (en) Method and reagent for identifying antibody combined with mutant antigen
WO2022054822A1 (en) Test kit having specificity improved by inhibiting false positives
US20210199652A1 (en) Test Kit For Detecting A Plurality Of Analytes
JP7226878B1 (en) Test method, immunochromatographic test strip, and immunochromatographic kit
CN114578046A (en) Novel coronavirus (SARS-CoV-2) antibody detection reagent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination